CNS Pharma: Jumps on orphan drug designation application for cancer drug

CNS Pharmaceuticals

23/04/2020 14:15

** Shares of biotech company  CNSP.O  jump 18% to $3.53 -
among top pct. gainers across U.S. exchanges
    ** Company submits orphan drug designation (ODD) application
to the FDA for its lead drug candidate, Berubicin  urn:newsml:reuters.com:*:nPn4sV9mNa
    ** The drug, previously known as RTA-744 and developed by
Reata Pharmaceuticals  RETA.O , was granted ODD for treatment of
a type of brain and spinal cord tumor 
    ** CNSP is trying to get ODD for the drug to treat the most
aggressive form of brain tumor, glioblastoma
    ** Company aims to start a mid-stage trial for Berubicin
later this year
    ** ODD provides a special status to a drug to treat a rare
disease or condition
    ** CNSP had lost 24.3% YTD, as of last close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))